3[1]Dennis M, Grasel S. Clinical pharmacology of gatifloxacin, a new fluoroquinolone[J]. Clinical Infect Dis, 2000;31:S51-8
4[2]Hosaka M, Yasue T, Fukuda H, Tomizawa H, Aoyama H, Hirai K. In vitro and in vivo antibacterial activities of AM-1166, a new 6-fluoro-8-methoxyquinolone[J]. Antimicrob Agents Chemother, 1992;36:2108-17
5[3]Wakabayashi E, Mitsuhashi S. In vitro antibacterial activities of AM-1155, a novel 6-fluoro-8-methoxyquinolone[J].Antimicrob Agents Chemother, 1994;38:594-601
6[4]Jones RN, Biedenbach DJ, Erwin ME, Beach ML, Pfaller MA. Activity of gatifloxacin against haemophilus influenzae and moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae[J]. J Clin Microbiol, 1999;37:1999-2002
7[5]National Commettee for Clinical Laboratory Standards[S]. 2002:99-103
8[6]Pfaller MA, Jones RN, Doern GV, Salazar JC. Survey of blood stream infections attribute to gram-positive cocci :frequency of occurrence and antimicrobial susceptibility of isolates collected 1997 in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program[J].Diagn Microbiol Infect Dis, 1999;33:283-97
9[7]Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN,et al. Survey of infections due to staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999[J].Clin Infect Dis, 2001;32:( Suppl 2):S114-32
